ALEC

Alector, Inc.
CAPPED RATING

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Alector, Inc. (ALEC) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
B
Factor Score 3.3 / 5.0
Growth
F
Factor Score 0.1 / 5.0
Profitability
B
Factor Score 3.4 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 6.9
EV / EBITDA 6.3
Rev Growth YoY N/M
Gross Margin 42.5%
Price Return 3M 16.3%
Price Return 12M 114.2%
Catalyst Signal 0.00
Market Cap $382.6M
TTM Revenue $173.5M
Price / Sales 2.2
ROE 47.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B (3.3) F (0.1) B (3.4) B- (3.0) C+ (2.6) C+ (2.5)
2026-11-10 B (3.4) F (0.1) B (3.4) B (3.4) C+ (2.6) C+ (2.6)
2026-11-03 B- (2.9) F (0.4) C- (1.9) B- (3.1) C+ (2.7) C (2.2)
2026-10-27 B- (2.9) F (0.4) C- (1.9) B- (3.1) C+ (2.6) C (2.2)
2026-10-20 B- (2.9) F (0.4) C- (1.9) C (2.5) C+ (2.6) C- (2.1)
Page 1 of 7